Wolfgang Miesbach: Octreotide as a First‑Line Systemic Option in VWD Patients With Angiodysplasia‑Related GI Bleeding
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:
“Could octreotide become a first‑line systemic option in VWD patients with angiodysplasia‑related GI bleeding?
Great talk by Sophie Susen at the EHA meeting in Florence on angiodysplasia‑related GI bleeding and the implications of the OCEAN trial for VWD.
OCEAN trial:
- Multicenter RCT in 62 patients with transfusion‑dependent angiodysplasia‑related anemia, Octreotide LAR 40 mg q4w vs standard care.
- About 50% reduction in transfusion requirements (11.0 vs 21.2 units), alongside fewer endoscopic procedures and hospitalizations, with a generally favourable safety profile.
What octreotide actually does
Octreotide, a long‑acting somatostatin analogue, reduces splanchnic blood flow and portal pressure, improves platelet aggregation, and exerts anti‑angiogenic effects via inhibition of VEGF and other growth factors.
This mechanistic profile makes it particularly attractive for chronic bleeding from GI angiodysplasia.
What this could mean for VWD
Even though VWD patients were not included in OCEAN, these robust data provide the best evidence we currently have for systemic therapy in angiodysplasia‑related bleeding and strongly support octreotide as a potential first‑line systemic option in this setting.
Case reports and small series in VWD already suggest benefit, but dedicated prospective trials in VWD with angiodysplasia are urgently needed to define efficacy, safety, and optimal positioning in future treatment algorithms.”
Find more posts featuring Wolfgang Miesbach on Hemostasis Today.
-
Sep 19, 2026, 18:03Manisha Madkaikar: Clinical, Hematological, and Molecular Features of Sickle β-Thalassemia
-
Sep 19, 2026, 17:24Jan Shawqi Goran: Understanding Beta Thalassemia Before Marriage Testing
-
Sep 19, 2026, 14:17Abdul Mannan: What Exactly Is a Platelet?
-
Sep 19, 2026, 13:39Keisuke Goda: Decoding Platelet Phenotypes in COVID-19 With Optofluidic Imaging
-
Sep 19, 2026, 13:30Targeted Thrombolysis Beyond tPA
-
Sep 19, 2026, 13:21Paul Armstrong: From Summer Studentship to Young Researcher
-
Sep 19, 2026, 13:06Rabiya Masood: Breaking the Cycle of Thalassemia Through Screening
-
Sep 19, 2026, 10:52Consuela A. Albright: The Critical Role of Black Blood Donors in Sickle Cell Treatment
-
Sep 19, 2026, 10:47Amber Yates: Inside Agios’ Partnership with the Sickle Cell Community